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Post-treatment changesAbstract Purpose: The purpose of this study was to investigate the diagnostic value of dynamic
contrast enhanced magnetic resonance imaging (DCE-MRI) in the differentiation between post-
treatment changes and recurrent salivary gland tumors. Patients and methods: A prospectively
designed study was conducted on 37 patients having salivary gland malignant tumors treated by
surgery or chemo/radiotherapy or both. All patients underwent conventional MRI and DCE-
MRI. The obtained DCE-MRI data were interpreted semi quantitatively (using time intensity
curves, TIC and time to peak TTP) and quantitatively (using wash in and washout rates). The
obtained TICs were classiﬁed into four types (A, B, C, and D). Results: There was a signiﬁcant sta-
tistical difference as regards TICs, wash in and washout rates of recurrent salivary gland tumors and
that of post treatment changes, whereas there was no signiﬁcant difference as regards TTP. Receiver
Operating Characteristic (ROC) analysis revealed cutoff points of >10.25, and >6.25 for the wash
in and washout rates used to differentiate recurrent tumors from post-treatment changes, respec-
tively. Conclusion: We concluded that DCE MRI has a valuable diagnostic value in the differenti-
ation of recurrent malignant salivary gland tumors from post-treatment changes, especially, for
cases that remain unsolved by conventional MR imaging techniques.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
The management of head and neck cancer involves multidisci-
plinary evaluation and treatment. Often tumor recurrence maynot be evident clinically until the recurrence is large enough to
be clinically palpable, and hence imaging plays an important
role in the post-treatment surveillance of head and neck can-
cers. Differentiating post-treatment changes from tumor recur-
rence with the use of imaging is challenging because of the
presence of altered anatomy secondary to resection and post-
surgical scarring. Furthermore, radiation therapy may induce
tissue distortions such as edema, inﬂammation, and ﬁbrosis,
478 S. Samir et al.which makes post-treatment images more difﬁcult to interpret
(1).
Conventional post-contrast MRI is currently used for dif-
ferentiating recurrent tumor from ﬁbrosis after treatment of
head and neck cancer. Although the anatomical information
derived from the conventional post-contrast MRI is valuable
morphologically, it lacks functional information. Hence, the
recent advances in head and neck imaging are shifting from
the morphological to the functional techniques, which are used
to assess the complex related processes in the cancer microen-
vironment such as hypoxia, and angiogenesis (2).
Dynamic contrast enhanced magnetic resonance imaging
(DCE-MRI), is an emerging imaging method used to assess
tumor angiogenesis. It relies on fast MRI sequences obtained
before, during and after the rapid intravenous administration
of a gadolinium based contrast agent (3) so that the variations
of MR signal intensity with time can be recorded for each
image voxel. As the agent enters into a tissue, it changes the
MR signal intensity from the tissue to a degree that depends
on its local concentration (4).
Dynamic contrast enhanced MRI (DCE-MRI) has been
investigated for the differentiation of tumor recurrence and
post-treatment ﬁbrosis in regions, other than head and neck,
such as the breast, pelvis, gastrointestinal and musculoskeletal
system (5,6). In the head and neck region, DCE-MRI is an
adjuvant clinical tool used in the evaluation of soft tissue neo-
plasms and lymph nodes, and is thought to be a useful predic-
tor of response to radiotherapy. It is also used to monitor the
treatment and distinguish post-therapeutic changes from
recurrent mass with greater conﬁdence (7–10).
The aim of this study was to investigate the role of dynamic
contrast enhanced magnetic resonance imaging (DCE-MRI) in
the differentiation between recurrent salivary gland tumors
and post-treatment changes.2. Patients and methods
2.1. Patients
Dynamic contrast enhanced imaging (DCE-MRI) and conven-
tional post-contrast MRI of salivary glands were performed
prospectively in 37 consecutive patients (22 males and 15
females) with treated malignant salivary gland tumors between
January 2014 and July 2015. Their age ranged 38–79 years. All
patients were referred to our department from the follow-up
clinics of the radiation therapy and oncology departments of
Mansoura University Hospitals. Patients were evaluated
because of recurrence of symptoms (n= 20) or abnormal
physical examination ﬁndings during routine follow-up
(n= 17). Three patients were excluded from the study due to
bad MR images caused by motion artifact in two patients
and because of claustrophobia in one patient. We obtained
the approval of the institutional review board of our hospital
and an informed consent from the patients before the study.
Our MR diagnoses were correlated with histopathological
ﬁndings in twenty-six patients (n= 26) or with, clinical
follow-up in 8 patients (n= 8). Histopathological diagnoses
were done by surgical biopsy in thirteen patients (n= 13), core
biopsy in seven patients (n= 7), and ﬁne needle aspiration
biopsy in six patients (n= 6). The selection of the site of
biopsy was guided by the imaging ﬁndings on conventionaland DCE-MR. The surgeons selected the biopsy site after dis-
cussing the MR ﬁndings with the radiologists. When there was
suspicion of more than one pathological condition, multiple
biopsies were taken from the suspicious sites. The time delay
between the biopsy and MR studies varied between 7 and
15 days.
Clinical follow-up for one year was considered as post-
treatment changes if there is no change or decrease in the size
of the lesion under question and no new lesions appeared and
are considered as a tumor recurrence if the lesion increased in
size or new lesions appeared.
2.2. MRI protocol & image interpretation
MR images were obtained with a superconducting 1.5 T MR
imaging unit (Philips Ingenia) using neck array coil for all
cases. Precontrast reference scan was ﬁrst performed through
the region of interest (ROI) and was followed by intravenous
injection of gadolinium dimeglumine (Meglumine Gadopente-
tate, Magnevist). The standard MR acquisition parameters
were as follows: Multiplanar (axial, coronal, and sagittal)
T2-weighted images, axial T2 fat-suppressed fast spin-echo
images (TR, 5000 ms; TE, 102 ms; averages, 2; matrix,
256  256; section thickness, 4.0 mm; and gap, 1.0 mm) and
axial T1-weighted images (TR, 675 ms; TE, 20 ms; averages,
2; section thickness, 4.0 mm; gap, 1.0 mm; matrix,
256  192). Conventional T1- and T2-weighted images were
followed by DCE-MRI. Then, post-contrast axial, sagittal
and coronal T1-weighted images were ﬁnally obtained.
Characterization of the lesions on the conventional MRI
was based upon morphological criteria regarding tumor vol-
ume, signal intensity (SI) in different sequences and enhance-
ment after Gd-DTPA. Areas with very high SI (equivalent to
water) on T2-weighted images were interpreted as necrosis or
cystic degeneration and the very low SI areas on T1- and
T2-weighted images were interpreted as ﬁbrosis. Lesions with
iso to hypointense areas on T1 and T2WI that showed
enhancement after contrast injection and positive mass effect
to its surroundings, were regarded as recurrent tumors.
2.3. DCE-MRI protocol
Using automatic injector, a single bolus dose of gadolinium
dimeglumine was injected intravenously, at a dose of 0.3 ml/kg
body weight and at an injection rate of 2.5 ml/s, followed by a
20 ml saline ﬂush.
A dynamic two dimensional, spoiled gradient recalled echo
(2D-SPGR) axial T1WI fat suppressed sequence was done with
total acquisition time of 240 s during bolus injection of the con-
trast agent. The imaging parameters are as follows: 10.4 ms
repetition time (TR), 2.3 ms echo time (TE), 30 ﬂip angle;
4 mm section thickness, section gap 1 mm, 180–240 mm ﬁeld
of view (FOV), and 256  128 mm matrix size.
2.4. Image post-processing
The sequential dynamic MR images were transferred into
Philips extended work space (EWS) 2.6 workstation using its
speciﬁc software. The ROI was manually placed in the solid
most enhancing portion of the lesion avoiding the necrotic
areas.
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quent dynamic MR images by automatically copying and past-
ing the initial ROI. Then, time intensity curves (TIC) including
their analyses were generated automatically using the machine
software. Wash-in rate (K trans) was derived from the ﬁrst
pass phase of signal intensity enhancement. It is deﬁned as
the rate of enhancement between 10% and 90% of the signal
intensity difference between maximum signal post-
enhancement (SI max) and signal intensity prior to enhance-
ment (SI base). Wash-out rate (K ep) was derived from the
enhancement signal decay phase. It is deﬁned as the rate of
mono exponential decay of the enhancement signal in the tis-
sue (11).
2.5. Image interpretation
The obtained DCE-MRI data were interpreted semi quantita-
tively and quantitatively. The semi quantitative interpretation
was done using time intensity curve (TIC) and time to peak
(TTP), while the quantitative interpretation was done by mea-
suring the K trans and K ep values. Each of the obtained TIC
was classiﬁed into four types (Fig. 1): type-A (gradual enhance-
ment curve), type-B (rapid enhancement with low washout
curve) and type-C (rapid enhancement with high washout
curve) and type-D (ﬂat curve) (12).
2.6. Statistical analysis
The statistical analysis of data was done using SPSS program
(Statistical Package of Social Science) version 17. Quantitative
data were presented as mean and standard deviation. To com-
pare between two groups, student t-test was used. To compare
between more than two groups, one way ANOVA test was
used. The Receiver Operating Characteristic (ROC) curves
were drawn to detect cutoff point for K trans and K ep values
used to differentiate recurrent tumors from post-treatment
changes. P value of 60.05 was considered to be statistically sig-
niﬁcant and P value <0.001 was considered highly signiﬁcant
in all analyses.Fig. 1 Types of tim3. Results
Dynamic contrast enhanced imaging (DCE-MRI) and conven-
tional post-contrast MRI of salivary glands were performed
prospectively in 37 consecutive patients (22 males and 15
females) with treated salivary gland tumors. Their age ranged
38–79 years, mean 59 years. Patients were evaluated because of
recurrence of symptoms (n= 20) or abnormal physical exam-
ination ﬁndings during routine follow-up (n= 17). Three
patients were excluded from the study due to bad MR images
caused by motion artifact in two patients and because of claus-
trophobia in one patient.
All the patients included in our study were treated from
salivary gland malignant tumors. These tumors were treated
with surgery alone in four patients (n= 4), radiation therapy
alone in thirteen patients (n= 13), or both surgery and radia-
tion therapies in the remaining seventeen patients (n= 17).
The tumors were located in; parotid gland (n= 24), sub-
mandibular gland (n= 4), and oral cavity (n= 6) Table 1.
Pathology of primary tumors was mucoepidermoid carcinoma
(n= 12), adenoid cystic carcinoma (n= 10), carcinoma in ex
pleomorphic adenoma (n= 8), and sarcoma (n= 4) Table 2.
The analysis of conventional post-contrast MR images of
the lesions was based on the morphological MR criteria illus-
trated in Table 3, where 16 lesions were diagnosed as tumor
recurrence, and 18 lesions as post-treatment changes with sen-
sitivity of 60% and speciﬁcity of 71% Table 4.
The semi quantitative assessment of dynamic post-contrast
enhanced MR data included analysis of time intensity curves
(TIC) and time to peak (TTP). There was a signiﬁcant statisti-
cal difference (P< 0.05) as regards TIC of salivary gland
tumor recurrence and that of post-treatment changes. TIC of
recurrent tumors showed Type C curves in eight patients
(n= 8, 40%), Type B curves in eight patients (n= 8, 40%)
and type A curves in four patients (n= 4, 20%). TIC of
post-treatment changes showed type B curves in ten patients
(n= 10, 71.4%) and type A curves in four patients (n= 4,
28.6%) Table 5. There was no signiﬁcant difference
(P= 0.007) as regards TTP between recurrent malignant sali-e intensity curves.
Table 1 Location and methods of treatment in 34 patients
with treated malignant salivary gland tumors.
Location of lesions
Parotid gland 24
Oral cavity 6
Submandibular gland 4
Total 34
Method of treatment
Surgery 4
Radiotherapy 13
Combined surgery & radiotherapy 17
Total 34
Table 2 Pathological types of the studied salivary gland
tumors.
Pathological type Number
Mucoepidermoid carcinoma 12
Adenoid cystic carcinoma 10
Carcinoma in ex-pleomorphic adenoma 8
Sarcoma 4
Total 34
Table 3 Conventional post-contrast MRI morphological
criteria used in our study for differentiation between tumor
recurrence and post-treatment changes.
MRI tumor character Number of lesions
Margin Well deﬁned (n= 6)
Ill deﬁned (n= 28)
T2 SI Low (n= 10)
High (n= 24)
Post-contrast Faint (n= 8)
Intense (n= 26)
Other ﬁndings (e.g.: bony invasion, nodal
mets., mass eﬀect)
Present (n= 12)
Absent (n= 22)
Table 5 The TICs obtained in our study for the recurrent
salivary gland tumors and for the post-treatment changes.
Type of TIC Recurrent tumors Post-treatment changes P value
No. % No. %
A 4 20 4 28.6 <0.05
B 8 40 10 71.4 <0.05
C 8 40 0 0 <0.05
D 0 0 0 0 <0.05
480 S. Samir et al.vary gland tumors and post-treatment changes. The ranges of
TTP of recurrent tumors were 78.30–145.00, median 80.15 and
the ranges of TTP of post-treatment changes were 119.30–
189.50, median 126.10 Table 6.
The quantitative assessment of dynamic post-contrast
enhanced MR data included analysis of wash in ratesTable 4 Sensitivity and speciﬁcity of conventional MRI in differe
gland tumors.
Recurrent tumors Post-treatment changes
Pathology MRI Pathology
20 16 14
True (+) = 12, True () = 10, False (+) = 4, False () = 8.(K trans), and washout rates (K ep). There was signiﬁcant dif-
ference (P= 0.01) as regards wash in rates between recurrent
malignant salivary gland tumors and post-treatment changes,
and also there was a signiﬁcant difference (P= 0.03) as
regards washout rates between recurrent tumors and post-
treatment changes Table 7. Receiver Operating Characteristic
(ROC) analysis revealed cutoff point of >10.25 for K trans
values used to differentiate recurrent tumors from post-
treatment changes, with 85.7% sensitivity, 70% speciﬁcity
and 76.5% accuracy. ROC analysis of K ep values revealed
cutoff point of >6.35 for differentiation of recurrent tumors
from post-treatment changes with 71.4% sensitivity, 75%
speciﬁcity and 73.3% accuracy Table 8 (Fig. 2).
4. Discussion
Imaging surveillance after treatment of head and neck tumors
is useful to detect residual or recurrent tumor, even when clin-
ical recurrence is not suspected (13). Also, the interpretation of
post-treatment follow-up imaging studies is complicated
because surgery can alter anatomy, and radiation/chemother-
apy can result in edema and ﬁbrosis. These post-treatment
changes can mimic tumor recurrence, and sometimes it is dif-
ﬁcult to distinguish these from residual or recurrent tumor
using conventional imaging (14).
We evaluated thirty-four patients with malignant salivary
gland tumors, after different treatment modalities, using con-
ventional and dynamic contrast enhanced MRI. The conven-
tional post-contrast MR diagnoses in our study, were based
only on the morphological MR criteria. According to these
morphological criteria, sixteen (n= 16) lesions were diagnosed
as recurrences of malignant salivary gland tumors, and eigh-
teen (n= 18) lesions as post-treatment changes with sensitivity
of 60% and speciﬁcity of 71%. These relatively low percent-
ages could be explained by at least three reasons. Firstly, the
presence of gadolinium enhancement was found in all recur-
rent tumors and in some of ﬁbrotic tissues, so this single mor-
phological character is not speciﬁc. Secondly ﬁbrosis wasntiation between post-treatment changes and recurrent salivary
Conventional MRI
MRI Sensitivity Speciﬁcity
18 60% 71%
Table 6 Ranges and median values of TTP obtained in recurrent salivary gland tumors and in post-treatment changes.
Time to peak (TTP) Recurrence Post-treatment changes P value
Range Median Range Median
78.30–145.00 80.15 119.30–189.50 126.10 0.07
Table 7 Ranges and median values of wash in (K trans) and wash out (K ep) in recurrent tumors and post-treatment changes.
Recurrence Post-treatment changes P value
Range Median Range Median
Wash in rate (K trans) (1/s) 8.70–16.30 12.05 5.50–11.10 8.40 0.01
Wash out rate (K ep) (1/s) 2.40–14.60 9.80 3.20–6.50 5.70 0.03
Table 8 Statistical analysis of wash in (K trans) and wash out (K ep) rates in differentiation of recurrent tumors and post-treatment
changes.
Area under the curve Cut oﬀ value Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy
Wash in rate (K trans) (1/s) 0.87 (0.55–1.0) >10.25 85.7 70.0 66.7 87.5 76.5
Wash out rate (K ep) (1/s) 0.83 (1.00–1.00) >6.35 71.4 75.0 71.4 75.0 73.3
PPV: positive predictive value, NPV: Negative predictive value.
Fig. 2 (a and b): ROC curves of wash in (a) and washout rates (b) in differentiation of recurrent salivary gland tumors and post-
treatment changes.
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of ﬁbrotic tissue displays low SI on T2WIS, which reﬂects its
low water content and decreased vascularity; however, ﬁbrosis
may show mixed SI and may appear as a mass lesion, so it can
be difﬁcult to recognize it only by signal intensity characters.
Lastly, the high T2 SI found in persistent inﬂammation in a
ﬁbrotic tissue can mimic high signal intensity pattern of recur-
rent tumor on conventional T2WIS.
Dynamic contrast enhanced imaging (DCE-MRI) produces
information about the vascularity of cancers and has the
potential to be used to detect and characterize tumors, and
evaluate treatment response (15,16). Different studies demon-
strated that dynamic contrast enhanced MRI is valuable for
the differentiation of tumor recurrence and post-treatment
ﬁbrosis in different regions such as breast, pelvis, muscu-
loskeletal system and in the head and neck regions (2,17).In this study we investigated the utility of DCE-MRI for
the differentiation of recurrent malignant salivary gland
tumors from post-treatment changes using two different ana-
lytical methods (the semiquantitative and the quantitative
methods). We ﬁrstly applied the semiquantitative approach
by plotting the signal intensity against time, to obtain the time
intensity curves (TIC). Then we proceeded to the quantitative
approach, using the contrast wash in (K trans) and washout
rates (K ep).
Many investigators used different approaches in the eval-
uation of TIC curves. Sasaki et al. (18) used visual analysis
and classiﬁcation of TIC to differentiate between benign and
malignant tumors. Takashima et al. (19) depended on the
time at which the curves displayed peak enhancement, and
classiﬁed TIC curves into ﬁve groups: type A, the curve
peaked at 0–30 s after the administration of contrast
482 S. Samir et al.medium; type B, the curve peaked at 30–60 s after the
administration of contrast medium; type C, the curve peaked
at 60–210 s after the administration of contrast medium;
type D, the curve displayed a gradual upward slope; and
type E, the curve was ﬂat. Kuhl et al. (20) presented another
approach, in which the shape of the entire time signal inten-
sity curve is visually assessed, yielding three different curves:
steady, plateau, and washout.
In agreement with our study, Eida et al. (11) classiﬁed TIC
curves into four types: type A (gradual enhancement), type B
(rapid enhancement and low washout), type C (rapid enhance-
ment and high washout), and type D (ﬂat). There was a signif-Fig. 3 Post-treatment changes after left total parotidectomy. (a and
hyperintense area in the region of left parotid gland (in a and b respectiv
heterogeneous enhancement of the lesion. (d) Axial delayed phase dyn
lesional enhancement. (e) Time signal intensity curve shows progressive
in and washout rates.icant difference (P< 0.5) as regards TIC between benign post-
treatment changes and recurrent tumors. Benign post-
treatment changes revealed type B curves in ten patients
(71.4%) and type A curves in four patients (28.6%) (Figs. 3
and 4), while 80% of malignant recurrent salivary gland
tumors revealed type B and C curves (Figs. 5 and 6).
Yabuuchi et al. (21) in a study of parotid gland tumors
agreed with our results, they regarded type A, B and D TIC
tumors as benign neoplasms and type C TIC tumors as malig-
nant neoplasms, and the sensitivity, speciﬁcity, accuracy, and
positive and negative predictive values were 71%, 86%,
82%, and 67% and 89% respectively.b) Axial T1WI, and T2WI show an ill-deﬁned hypointense and
ely). (c) Axial post-contrast T1WI with fat suppression shows mild
amic post-contrast T1WI with fat suppression shows progressive
pattern of enhancement (type-A curve). (f) Measurements of wash
Fig. 4 Post-treatment changes in left sublingual carcinoma ex-pleomorphic adenoma. (a and b) Axial T1WI with fat suppression and
T2WI showing ill-deﬁned area of mixed signal intensity (a) and of high SI (b) in the left sublingual region. (c) Axial post-contrast T1WI
with fat suppression shows mild enhancement of the lesion. (d) Axial delayed phase dynamic post-contrast T1WI with fat suppression
shows progressive lesional enhancement. (e) Time signal intensity curve shows progressive pattern of enhancement (type-A curve). (f)
Measurements of wash in and washout rates.
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head and neck tumors, they found that benign lesions pre-
sented curves type D, A and C in disagreement with our study,
while malignant tumors showed type C and B curves which is
in agreement with the present study. The differences in types of
curves happened between our study and the study by Sasaki
et al. could be explained by the large number of Warthin
tumors contained in their study which gave type C curve.
TIC shape analysis does not provide absolute measures. It
is dependent, and is affected by the length of the scan, and
the scan parameters (TR/ﬂip angle), and all these factors can
inﬂuence the ﬁnal shape of the curve, resulting in the same tis-
sue possibly being classiﬁed differently when using different
parameters (22).
Semiquantitative analysis in our study showed that time
to peak (TTP), is not statistically signiﬁcant in differentiat-
ing benign post-treatment changes from salivary gland
tumor recurrence. However the quantitative assessment of
dynamic post-contrast enhanced MR data including the
analysis of wash in rates (K trans), and washout rates (K
ep) was proved to be signiﬁcant in differentiating both enti-
ties. We found a signiﬁcant difference (P= 0.01) as regardswash in rates between recurrent malignant salivary gland
tumors and post-treatment changes, and also there was a
signiﬁcant difference (P= 0.03) as regards washout rates
between recurrent tumors and post-treatment changes.
Receiver Operating Characteristic (ROC) analysis revealed
cutoff point of >10.25 for K trans values used to differen-
tiate recurrent salivary gland tumors from post-treatment
changes, with 85.7% sensitivity, 70% speciﬁcity and 76.5%
accuracy. ROC analysis of K ep values revealed cutoff point
of >6.35 for differentiation of recurrent salivary gland
tumors from post-treatment changes with 71.4% sensitivity,
75% speciﬁcity and 73.3% accuracy.
These results are in agreement with those of Rouviere et al.
(23); they stated that there was no difference in time to peak
(TTP) in differentiating benign from malignant prostatic tissue
and the contrast washout was signiﬁcantly more rapid in
tumor than in normal peripheral zone. In another study of
the role of DCE-MRI in head and neck tumors, Tomura
et al. (24), concluded that maximum slope of increase (which
corresponded to contrast washout rates in our study) is lower
in non-tumor involved lesions, than in the involved ones,
which is also in agreement with our results.
Fig. 5 Recurrent left parotid adenoid cystic carcinoma. (a and b) Axial T1WI and T2WI showing lobulated mass lesion of intermediate
SI (a) and of heterogenous high SI (b) in the left parotid region. (c) Axial post-contrast T1WI with fat suppression shows mild
heterogenous enhancement. (d) Axial delayed phase dynamic post-contrast T1WI with fat suppression shows progressive lesional
enhancement. (e) Time signal intensity curve shows progressive pattern of enhancement with rapid wash out (type-C curve). (f)
Measurements of wash in and wash out rates.
484 S. Samir et al.Our study had some limitations, we included salivary gland
cancers with various locations, treatment modalities, and inter-
vals between last treatment and imaging, and this heterogene-
ity could limit the standardization of our results. Another
limitation of our present study was that the selection of opti-
mal sites for data sampling and localization of ROIs would
affect the consistent acquisition of reliable DCE data. The
reproducibility of the quantitative cutoff levels of K trans
and K ep in our results might not be transferable to other insti-
tutions, as the analysis of data generated by DCE-MRI is not
fully standardized yet (22). And however the semiquantitative
data have the advantage of being simple to obtain, but are not
readily transferable between different MRI scanners andradiofrequency coils because the baseline signal from the tissue
will vary between systems. In addition, they do not take into
account the underlying T1 value of the tissue being studied,
and do not accurately indicate the tissue concentrations of
gadolinium present (25).5. Conclusion
We concluded that DCE-MRI has a valuable diagnostic value
in the differentiation of recurrent malignant salivary gland
tumors from post-treatment changes, especially, for cases that
remain unsolved by conventional MR imaging techniques.
Fig. 6 Recurrent Right parotid mucoepidermoid carcinoma. (a) Axial T1WI shows a large mass of intermediate SI and a focus of high
SI of hemorrhage in the RT parotid region. (b) Axial T2WI shows heterogenous high SI of the lesion. (c and d) Axial post-contrast T1WI
with fat suppression (c) and axial delayed phase dynamic post-contrast T1WI with fat suppression (d) showing progressive lesional
enhancement. (e) Time signal intensity curve shows progressive pattern of enhancement with rapid wash out (type-C curve). (f)
Measurements of wash in and wash out rates.
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